Trinity Financial Advisors LLC Sells 1,848 Shares of Johnson & Johnson (NYSE:JNJ)

Trinity Financial Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 68.3% during the first quarter, HoldingsChannel reports. The fund owned 856 shares of the company’s stock after selling 1,848 shares during the quarter. Trinity Financial Advisors LLC’s holdings in Johnson & Johnson were worth $142,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Bard Financial Services Inc. grew its position in shares of Johnson & Johnson by 0.3% in the 1st quarter. Bard Financial Services Inc. now owns 100,317 shares of the company’s stock valued at $16,637,000 after buying an additional 289 shares during the last quarter. USA Financial Formulas grew its position in shares of Johnson & Johnson by 24.7% in the 1st quarter. USA Financial Formulas now owns 1,434 shares of the company’s stock valued at $238,000 after buying an additional 284 shares during the last quarter. Curbstone Financial Management Corp grew its position in shares of Johnson & Johnson by 0.7% in the 1st quarter. Curbstone Financial Management Corp now owns 26,921 shares of the company’s stock valued at $4,465,000 after buying an additional 189 shares during the last quarter. CX Institutional grew its position in shares of Johnson & Johnson by 6.6% in the 1st quarter. CX Institutional now owns 62,134 shares of the company’s stock valued at $10,304,000 after buying an additional 3,821 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Johnson & Johnson by 75.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,601,872 shares of the company’s stock valued at $265,654,000 after purchasing an additional 690,168 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Raymond James cut their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday, April 14th. Morgan Stanley upped their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Barclays cut their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $155.19 on Thursday. The company has a market cap of $373.41 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The business has a 50 day moving average price of $153.56 and a 200-day moving average price of $153.70. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.